Androgen receptor variants and microenvironment in prostate cancer

Schreyer, Edwige; Erdmann, Eva; Cottard, Félicie; Delbecque, Marine; Berthélémy, Pauline Ould Madi; Kurtz, Jean‐Emmanuel; Céraline, Jocelyn

doi:10.1530/endoabs.42.p14

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EMT is crucial in PCa progression and resistance to castration [ 75 , 76 , 77 , 78 , 79 , 80 , 81 ]. In PCa, EMT emerges as a result of selection pressure of full‐length AR inhibition during castration [ 25 , 26 , 68 , 73 , 82 , 83 , 84 , 85 ].…”

Section: Discussionmentioning

confidence: 99%

Androgen receptor‐mediated transcriptional repression targets cell plasticity in prostate cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

Androgen receptor (AR) signaling remains the key therapeutic target in the management of hormone-naïve-advanced prostate cancer (PCa) and castration-resistant PCa (CRPC). Recently, landmark molecular features have been reported for CRPC, including the expression of constitutively active AR variants that lack the ligand-binding domain. Besides their role in CRPC, AR variants lead to the expression of genes involved in tumor progression. However, little is known about the specificity of their mode of action compared with that of wild-type AR (AR-WT). We performed AR transcriptome analyses in an androgen-dependent PCa cell line as well as cross-analyses with publicly available RNA-seq datasets and established that transcriptional repression capacity that was marked for AR-WT was pathologically lost by AR variants. Functional enrichment analyses allowed us to associate AR-WT repressive function to a panel of genes involved in cell adhesion and epithelial-to-mesenchymal transition. So, we postulate that a less documented AR-WT normal function in prostate epithelial cells could be the repression of a panel of genes linked to cell plasticity and that this repressive function could be pathologically abrogated by AR variants in PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

Androgen receptor‐mediated transcriptional repression targets cell plasticity in prostate cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Aging and high-fat diets have been suggested as epidemiological risk factors that contribute to the rise of prostate cancer incidence in Taiwan [ 3 , 4 ]. Although androgen receptors (ARs) and the androgen signaling axis were the traditional focus for prostate cancer research and clinical therapy development [ 5 , 6 , 7 , 8 ], genome-wide assays have identified multiple highly penetrant genes (HPGs) and high-risk single nucleotide polymorphisms (SNPs) associated with prostate cancer risk in the prostate cancer-diagnosed genome [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics

Chou

Yang

Lin

et al. 2020

IJERPH

View full text Add to dashboard Cite

Prostate cancer is one of the major cancers of the genitourinary tract. High-mobility group box 1 (HMGB1) was suggested as a promising therapeutic target for prostate cancer. In this study, we aim to elucidate the associations of HMGB1 single nucleotide polymorphisms (SNPs) with prostate cancer susceptibility and clinicopathological characteristics. The HMGB1 SNPs rs1412125, rs2249825, rs1045411, and rs1360485 in 579 prostate cancer patients and 579 cancer-free controls were analyzed with real-time polymerase chain reactions (real-time PCR). All of the data were evaluated with SAS statistical software. Our results showed that the HMGB1 rs1045411 T allele genotype was significantly associated with advanced pathologic T stage (odds ratio (OR) = 1.433, 95% confidence interval (CI) = 1.021–2.012; p = 0.037) and pathologic N1 stage (OR = 2.091, 95% CI = 1.160–3.767; p = 0.012), and the rs1360485 polymorphic CT + TT genotype was associated with pathologic Gleason grade group (4 + 5) (OR = 1.583, 95% CI = 1.017–2.462; p = 0.041), pathologic T stage (3 + 4) (OR = 1.482, 95% CI = 1.061–2.070; p = 0.021), and pathologic N1 stage (OR = 2.131, 95% CI = 1.178–3.852; p = 0.011) compared with their wild-type carriers. In conclusion, our results revealed that the HMGB1 SNPs were associated with the clinical status of prostate cancer. The HMGB1 SNPs may have the potential to predict prostate cancer disease progression.

show abstract

Androgen receptor variants and microenvironment in prostate cancer

Cited by 2 publications

References 0 publications

Androgen receptor‐mediated transcriptional repression targets cell plasticity in prostate cancer

Androgen receptor‐mediated transcriptional repression targets cell plasticity in prostate cancer

The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics

Contact Info

Product

Resources

About